Potentia Pharmaceuticals, Inc.
Records under this name other than patents Potentia Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 7 of 7 · Back to Potentia Pharmaceuticals, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,168,584 | Methods of Treating Age-Related Macular Degeneration by Compstatin and Analogs Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 8,580,735 | Local Complement Inhibition for Treatment of Complement-Mediated Disorders Formerly held In force · High confidence | In force | High confidence | |
| US 9,056,076 | A method of treating age-related macular degeneration comprising administering a compstatin analog Formerly held Term ended Ended no later than Oct 25, 2026 · Medium confidence | Term ended | Ended no later than Oct 25, 2026 | Medium confidence |
| US 10,407,466 | Methods of Selecting Compstatin Mimetics Formerly held Term ended Term ended Oct 6, 2026 · Medium confidence | Term ended | Term ended Oct 6, 2026 | Medium confidence |
| US 8,198,020 | Compositions and Methods for Enhancing Phagocytosis or Phagocyte Activity Formerly held Term ended Term ended Jan 25, 2026 · High confidence | Term ended | Term ended Jan 25, 2026 | High confidence |
| US 8,043,609 | Viral complement control proteins for eye disorders Lapsed on the fee record Ended Oct 25, 2015 · USPTO record | Lapsed on the fee record | Ended Oct 25, 2015 | USPTO record |
| US 7,947,267 | Viral complement control proteins for eye disorders Lapsed on the fee record Ended May 24, 2015 · USPTO record | Lapsed on the fee record | Ended May 24, 2015 | USPTO record |